VRDN
$28.60
Viridian Therapeutics, Inc.
Recent News
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June […]
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders
Viridian Therapeutics reported fourth-quarter 2025 revenue of US$132,000 and a net loss of US$120.36 million, while full-year revenue rose to US$70.85 million alongside a net loss of US$342.6 million. The company also highlighted progress for thyroid eye disease programs, including a June 30, 2026 PDUFA date for veligrotug and ongoing Phase 3 trials for elegrobart. We’ll now examine how Viridian’s advancing thyroid eye disease pipeline and detailed 2025 results shape the company’s evolving...
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -20.67% and -99.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +55.56% and +14.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?